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To the editor
Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a mole-
cule present on activated T cells, is a homologue of
CD28 that inhibits B7 co-stimulatory molecules
expressed on mature antigen presenting cells. Ipilimu-
mab is a fully humanized monoclonal antibody against
CTLA-4 [1]. Ipilimumab is FDA approved in the United
States for treatment of unresectable or metastatic mela-
noma [1,2]. We report the first case of large granular
lymphocytosis with severe neutropenia following ipili-
mumab therapy.
A 74 year old female presented with relapsed mela-
noma in the left lower extremity in Sept 2009. She was
treated with temozolomide. In July 2010, she developed
metastatic melanoma. She was enrolled onto a clinical
trial and treated with ipilimumab on Sept 16, 2010 and
October 7, 2010 at 3 mg/kg (232 mg per treatment)
q3wks. Her baseline CBC was normal. At the start of
the third dose, there was a significant decline in the
patient ’s WBC count. Therefore ipilimumab was
stopped. The patient was admitted on November 2,
2010 with fever, malaise and generalized weakness. She
was noted to have Hgb 6.2 G/dL, WBC 1.3 × 106 /L
with no neutrophils, and platelet count of 158 × 106
/L. The patient had a bone marrow evaluation which
showed mildly hypercellular cellular marrow with
marked myeloid hypoplasia/aplasia, relative erythroid
hyperplasia and mild megakaryocytic atypia. Karyotype
analysis demonstrated 46 XX, but FISH analysis
showed a 5q31 deletion with EGR1 gene deletion in
14% of the cells. Flow cytometry study showed 46%
T-cells with 20% large granular lymphocytes and 12%
NK cells. A T-cell receptor gene study by Genzyme
showed clonal T-cell receptor gamma gene rearrange-
ment. These findings were consistent with myelodys-
plasia and large granular lymphocytosis with severe
neutropenia. In addition to broad-spectrum antibiotics
and G-CSF, the patient was given IVIG without signifi-
cant response. The CBC on Nov 17 was WBC 0.8, Hgb
8.9, and Platelets 271. CT scans revealed bilateral locu-
lated pleural effusion for which she had thoracentesis.
The patient was started on treatment on Nov 18, 2010
with IV methylprednisolone 1 mg/kg q12h, and equine
ATG at 15 mg/kg daily × 4 days, as well as cyclospor-
ine 2.5 mg/kg twice daily. G-CSF and antibiotics were
continued. The WBC rose to 2.6 the day after ATG
was completed (Table 1). Two days later, her WBC
was 15.3. G-CSF was stopped. Her general condition
improved gradually. She was discharged 11 days later.
She remained on cyclosporine and low dose predni-
sone. Three months later, she remained only on low
dose prednisone. Her CBC showed WBC 12.1, Hgb
11.9, and Platelets 259 at last follow-up visit on Feb
23, 2011.
The most common adverse events associated with
ipilimumab are immune-related, including enterocoli-
tis, hepatitis, dermatitis and hypophysitis. Severe hema-
tological toxicity is rare. One case of severe
autoimmune-related neutropenia was reported and the
patient responded rapidly to IVIG infusion, but not to
steroids [3]. This case of large granular lymphocytosis
with severe neutropenia did not respond to IVIG and
steroids, but had a rapid response to ATG, steroids,
and cyclosporine immunosuppressive therapy. It is
unclear whether the myelodysplasia findings on the
bone marrow biopsy were related to the ipilimumab* Correspondence: DELONG_LIU@NYMC.EDU
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therapy or to previous chemotherapy with
temozolomide.
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11/17/2010 0.8 8.9 271
11/18/2010 0.9 9.0 280
11/19/2010 0.1 8.3 142
11/20/2010 0.3 8.1 90
11/21/2010 0.7 8.8 92
11/22/2010 2.6 1.2 8.5 60
11/23/2010 15.3 6.7 8.7 70
11/24/2010 30.3 19.4 8.2 73
11/25/2010 35.9 7.8 55
11/27/2010 28.4 25.8 9.7 43
11/28/2010 23.6 20.5 10.1 41
11/30/2010 15.0 13.8 8.5 77
12/1/2010 12.4 8.8 82
12/2/2010 8.8 7.2 7.9 61
12/17/2010 2.7 1.6 9.8 59
12/21/2010 7.0 5.3 10.8 157
2/17/2011 6.5 5.6 10.1 194
2/23/2011 12.1 10.3 11.9 259
Abbreviations: WBC: white blood cell; ANC: absolute neutrophils count; Hgb:
hemoglobin; Plt: platelet.
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